Current advances of liquid biopsies in prostate cancer: Molecular biomarkers

Ilic, 2018, Prostate cancer screening with prostate-specific antigen (PSA) test: a systematic review and meta-analysis, Bmj, 362, k3519, 10.1136/bmj.k3519 Leal, 2018, Estimating the sensitivity of a prostate cancer screening programme for different PSA cut-off levels: A UK case study, Cancer Epidemiol., 52, 99, 10.1016/j.canep.2017.12.002 Amling, 2004, Pathologic variables and recurrence rates as related to obesity and race in men with prostate cancer undergoing radical prostatectomy, J. Clin. Oncol., 22, 439, 10.1200/JCO.2004.03.132 Beebe-Dimmer, 2009, Racial differences in risk of prostate cancer associated with metabolic syndrome, Urol., 74, 185, 10.1016/j.urology.2009.03.013 Whittemore, 1995, Prostate cancer in relation to diet, physical activity, and body size in blacks, whites, and Asians in the United States and Canada, J. Natl. Cancer Inst., 87, 652, 10.1093/jnci/87.9.652 Esserman, 2014, Addressing overdiagnosis and overtreatment in cancer: a prescription for change, Lancet Oncol., 15, e234, 10.1016/S1470-2045(13)70598-9 Lone, 2022, Liquid biopsy: a step closer to transform diagnosis, prognosis and future of cancer treatments, Mol. Cancer, 21, 79, 10.1186/s12943-022-01543-7 Liu, 2017, Circulating tumor cells in prostate cancer: Precision diagnosis and therapy (Review), Oncol. Lett., 14, 1223, 10.3892/ol.2017.6332 Theil, 2021, In vivo isolation of circulating tumor cells in patients with different stages of prostate cancer, Oncol. Lett., 21, 357, 10.3892/ol.2021.12618 Maas, 2017, Circulating tumor cells and their role in prostate cancer, Asian J. Androl., 21, 24 Antonarakis, 2014, AR-V7 and resistance to enzalutamide and abiraterone in prostate cancer, N. Engl. J. Med., 371, 1028, 10.1056/NEJMoa1315815 Rzhevskiy, 2022, Isolation of Circulating Tumor Cells from Seminal Fluid of Patients with Prostate Cancer Using Inertial Microfluidics, Cancers, 14, 3364, 10.3390/cancers14143364 Hodson, 2016, Precision medicine, Nature, 537, S49, 10.1038/537S49a Lee, 2020, Integrated RNA and metabolite profiling of urine liquid biopsies for prostate cancer biomarker discovery, Sci. Rep., 10, 3716, 10.1038/s41598-020-60616-z Kwapisz, 2017, The first liquid biopsy test approved. Is it a new era of mutation testing for non-small cell lung cancer?, Ann. Transl. Med., 5, 46, 10.21037/atm.2017.01.32 Alix-Panabières, 2013, Circulating Tumor Cells: Liquid Biopsy of Cancer, Clin. Chem., 59, 110, 10.1373/clinchem.2012.194258 Gingras, 2015, Liquid biopsy: will it be the ‘magic tool’ for monitoring response of solid tumors to anticancer therapies?, Curr. Opin. Oncol., 27, 560, 10.1097/CCO.0000000000000223 Pyykkö, 2014, Cerebrospinal Fluid Biomarker and Brain Biopsy Findings in Idiopathic Normal Pressure Hydrocephalus, PLOS ONE, 9, 10.1371/journal.pone.0091974 Karachaliou, 2015, Real-time liquid biopsies become a reality in cancer treatment. Ann Transl Med, Mar, 3, 36 Crowley, 2013, Liquid biopsy: monitoring cancer-genetics in the blood, Nat. Rev. Clin. Oncol., 10, 472, 10.1038/nrclinonc.2013.110 Mouraviev, 2016, Clinical prospects of long noncoding RNAs as novel biomarkers and therapeutic targets in prostate cancer, Prostate Cancer Prostatic Dis., 19, 14, 10.1038/pcan.2015.48 Mahmud, 2021, Rapid Diagnosis of Prostate Cancer Disease Progression Using Paper Spray Ionization Mass Spectrometry, Anal. Chem., 93, 7774, 10.1021/acs.analchem.1c00943 Ignatiadis, 2021, Liquid biopsy enters the clinic — implementation issues and future challenges, Nat. Rev. Clin. Oncol., 18, 297, 10.1038/s41571-020-00457-x Fujita, 2018, Urinary biomarkers of prostate cancer, Int. J. Urol., 25, 770, 10.1111/iju.13734 Wei, 2015, Urinary biomarkers for prostate cancer, Curr. Opin. Urol., 25, 77, 10.1097/MOU.0000000000000133 Gurung, 2021, The exosome journey: from biogenesis to uptake and intracellular signalling, Cell Commun. Signal., 19, 47, 10.1186/s12964-021-00730-1 Zhang, 2019, Exosomes: biogenesis, biologic function and clinical potential, Cell Biosci., 9, 19, 10.1186/s13578-019-0282-2 Kalluri, 2020, The biology, function, and biomedical applications of exosomes, Science, 367, 10.1126/science.aau6977 Nilsson, 2009, Prostate cancer-derived urine exosomes: a novel approach to biomarkers for prostate cancer, Br. J. Cancer, 100, 1603, 10.1038/sj.bjc.6605058 Gan, 2022, Effective Diagnosis of Prostate Cancer Based on mRNAs From Urinary Exosomes. Original Research, Front. Med., 9, 10.3389/fmed.2022.736110 Øverbye, 2015, Identification of prostate cancer biomarkers in urinary exosomes, Oncotarget, 6, 30357, 10.18632/oncotarget.4851 Motamedinia, 2016, Urine Exosomes for Non-Invasive Assessment of Gene Expression and Mutations of Prostate Cancer, PLoS One, 11, 10.1371/journal.pone.0154507 Xu, 2021, Urinary Exosomes Diagnosis of Urological Tumors: A Systematic Review and Meta-Analysis, Front. Oncol., 11 Salvi, 2021, Detection and Investigation of Extracellular Vesicles in Serum and Urine Supernatant of Prostate Cancer Patients, Diagn. (Basel), 11, 466 McKiernan, 2020, A urine-based Exosomal gene expression test stratifies risk of high-grade prostate Cancer in men with prior negative prostate biopsy undergoing repeat biopsy, BMC Urol., 20, 138, 10.1186/s12894-020-00712-4 Hendriks, 2016, Comparative analysis of prostate cancer specific biomarkers PCA3 and ERG in whole urine, urinary sediments and exosomes, Clin. Chem. Lab. Med., 54, 483, 10.1515/cclm-2015-0599 Mitchell, 2009, Can urinary exosomes act as treatment response markers in prostate cancer?, J. Transl. Med., 7, 4, 10.1186/1479-5876-7-4 Jin, 2022, Urine Exosomal AMACR Is a Novel Biomarker for Prostate Cancer Detection at Initial Biopsy, Original Res. Front. Oncol., 12, 904315, 10.3389/fonc.2022.904315 Wang, 2017, Exosomal proteins as prostate cancer biomarkers in urine: From mass spectrometry discovery to immunoassay-based validation, Eur. J. Pharm. Sci., 98, 80, 10.1016/j.ejps.2016.09.023 Woo, 2019, GATA2 exosomal mRNA: A novel urine biomarker for the diagnosis of clinically significant prostate cancer, J. Clin. Oncol., 37, 18, 10.1200/JCO.2019.37.7_suppl.18 Fujita, 2017, Proteomic analysis of urinary extracellular vesicles from high Gleason score prostate cancer, Sci. Rep., 17 Skotland, 2017, Molecular lipid species in urinary exosomes as potential prostate cancer biomarkers, Eur. J. Cancer, 70, 122, 10.1016/j.ejca.2016.10.011 Li, 2021, Identification of Urinary Exosomal miRNAs for the Non-Invasive Diagnosis of Prostate Cancer, Cancer Manag. Res., 13, 25, 10.2147/CMAR.S272140 Kim, 2021, Urinary exosomal microRNA profiling in intermediate-risk prostate cancer, Sci. Rep., 11, 7355, 10.1038/s41598-021-86785-z Rodríguez, 2017, Identification of non-invasive miRNAs biomarkers for prostate cancer by deep sequencing analysis of urinary exosomes, Mol. Cancer, 16, 156, 10.1186/s12943-017-0726-4 Fredsøe, 2018, Diagnostic and Prognostic MicroRNA Biomarkers for Prostate Cancer in Cell-free Urine, Eur. Urol. Focus, 4, 825, 10.1016/j.euf.2017.02.018 Stuopelytė, 2016, Detection of miRNAs in urine of prostate cancer patients, Medicina, 52, 116, 10.1016/j.medici.2016.02.007 Holdmann, 2022, MicroRNAs from urinary exosomes as alternative biomarkers in the differentiation of benign and malignant prostate diseases, J. Circ. Biomark., 11, 5, 10.33393/jcb.2022.2317 Bryant, 2012, Changes in circulating microRNA levels associated with prostate cancer, Br. J. Cancer, 106, 768, 10.1038/bjc.2011.595 Wani, 2017, Urinary-exosomal miR-2909: A novel pathognomonic trait of prostate cancer severity, J. Biotechnol., 259, 135, 10.1016/j.jbiotec.2017.07.029 Samsonov, 2016, Lectin-induced agglutination method of urinary exosomes isolation followed by mi-RNA analysis: Application for prostate cancer diagnostic, Prostate, 76, 68, 10.1002/pros.23101 Işın, 2015, Exosomal lncRNA-p21 levels may help to distinguish prostate cancer from benign disease, Front. Genet., 6, 168 Li, 2016, Exosomal microRNA-141 is upregulated in the serum of prostate cancer patients, Onco. Targets Ther., 9, 139 Miyamae, 2015, Plasma microRNA profiles: identification of miR-744 as a novel diagnostic and prognostic biomarker in pancreatic cancer, Br. J. Cancer, 113, 1467, 10.1038/bjc.2015.366 Paunescu, 2019, Biomarker Potential of Plasma MicroRNA-150-5p in Prostate Cancer, Medicina (Kaunas), 55, 564, 10.3390/medicina55090564 Abramovic, 2021, MiR-182-5p and miR-375-3p Have Higher Performance Than PSA in Discriminating Prostate Cancer from Benign Prostate Hyperplasia, Cancers (Basel), 13, 2068, 10.3390/cancers13092068 Wang, 2016, MicroRNA-410-5p as a potential serum biomarker for the diagnosis of prostate cancer, Cancer Cell Int., 16, 12, 10.1186/s12935-016-0285-6 Guo, 2020, The Identification of Plasma Exosomal miR-423-3p as a Potential Predictive Biomarker for Prostate Cancer Castration-Resistance Development by Plasma Exosomal miRNA Sequencing, Front. Cell Dev. Biol., 8 Mohammadi Torbati, 2019, Circulating miR-20a and miR-26a as Biomarkers in Prostate Cancer, Asian Pac. J. Cancer Prev., 20, 1453, 10.31557/APJCP.2019.20.5.1453 Luo, 2019, Characterization of a Prostate- and Prostate Cancer-Specific Circular RNA Encoded by the Androgen Receptor Gene, Mol. Ther. Nucleic Acids, 18, 916, 10.1016/j.omtn.2019.10.015 Jiang, 2020, Upregulated circZMIZ1 promotes the proliferation of prostate cancer cells and is a valuable marker in plasma, Neoplasma, 67, 68, 10.4149/neo_2019_190213N116 Xie, 2022, CircSMARCC1 facilitates tumor progression by disrupting the crosstalk between prostate cancer cells and tumor-associated macrophages via miR-1322/CCL20/CCR6 signaling, Mol. Cancer, 21, 173, 10.1186/s12943-022-01630-9 Kong, 2020, Circular RNA circFOXO3 promotes prostate cancer progression through sponging miR-29a-3p, J. Cell. Mol. Med., 24, 799, 10.1111/jcmm.14791 Al-Qatati, 2017, Plasma microRNA signature is associated with risk stratification in prostate cancer patients, Int. J. Cancer, 141, 1231, 10.1002/ijc.30815 Matin, 2018, A Plasma Biomarker Panel of Four MicroRNAs for the Diagnosis of Prostate Cancer, Sci. Rep., 8, 6653, 10.1038/s41598-018-24424-w Barceló, 2019, Semen miRNAs Contained in Exosomes as Non-Invasive Biomarkers for Prostate Cancer Diagnosis, Sci. Rep., 9, 10.1038/s41598-019-50172-6 Barceló, 2020, Seminal plasma microRNAs improve diagnosis/prognosis of prostate cancer in men with moderately altered prostate-specific antigen, Am. J. Transl. Res., 12, 2041 McKiernan, 2016, A Novel Urine Exosome Gene Expression Assay to Predict High-grade Prostate Cancer at Initial Biopsy, JAMA Oncol., 2, 882, 10.1001/jamaoncol.2016.0097 Joshi, 2020, In silico analysis of long non-coding RNAs in medulloblastoma and its subgroups, Neurobiol. Dis., 141, 10.1016/j.nbd.2020.104873 Juracek, 2022, Urinary microRNAs and Their Significance in Prostate Cancer Diagnosis: A 5-Year Update, Cancers (Basel), 14, 10.3390/cancers14133157 Srivastava, 2013, MicroRNA profiling in prostate cancer--the diagnostic potential of urinary miR-205 and miR-214, PLoS One, 8, 10.1371/journal.pone.0076994 Wang, 2022, Diagnostic Value of Prostate-Specific Antigen Combined with Plasma miRNA-149 Expression in Patients with Prostate Cancer Based on Experimental Data and Bioinformatics, Contrast Media Mol. Imaging, 2022 Zhang, 2020, Role of the DNA damage response in prostate cancer formation, progression and treatment, Prostate Cancer Prostatic Dis., 23, 24, 10.1038/s41391-019-0153-2 Fan, 2004, Defective DNA strand break repair after DNA damage in prostate cancer cells: implications for genetic instability and prostate cancer progression, Cancer Res., 64, 8526, 10.1158/0008-5472.CAN-04-1601 Crocetto, 2022, Liquid Biopsy in Prostate Cancer Management—Current Challenges and Future Perspectives, Cancers, 14, 3272, 10.3390/cancers14133272 Carreira, 2014, Tumor clone dynamics in lethal prostate cancer, Sci. Transl. Med., 6, 254ra125, 10.1126/scitranslmed.3009448 Wyatt, 2017, Concordance of Circulating Tumor DNA and Matched Metastatic Tissue Biopsy in Prostate Cancer, J. Natl. Cancer Inst., 109, 10.1093/jnci/djx118 Jayaram, 2021, Plasma tumor gene conversions after one cycle abiraterone acetate for metastatic castration-resistant prostate cancer: a biomarker analysis of a multicenter international trial, Ann. Oncol., 32, 726, 10.1016/j.annonc.2021.03.196 Conteduca, 2020, Plasma tumour DNA as an early indicator of treatment response in metastatic castration-resistant prostate cancer, Br. J. Cancer, 123, 982, 10.1038/s41416-020-0969-5 Bjerre, 2020, Epigenetic Analysis of Circulating Tumor DNA in Localized and Metastatic Prostate Cancer: Evaluation of Clinical Biomarker Potential, Cells, 9, 10.3390/cells9061362 Haldrup, 2018, Biomarker potential of ST6GALNAC3 and ZNF660 promoter hypermethylation in prostate cancer tissue and liquid biopsies, Mol. Oncol., 12, 545, 10.1002/1878-0261.12183 Chen, 2021, Cell-free DNA concentration and fragment size as a biomarker for prostate cancer, Sci. Rep., 11, 5040, 10.1038/s41598-021-84507-z Kwee, 2012, Measurement of circulating cell-free DNA in relation to 18F-fluorocholine PET/CT imaging in chemotherapy-treated advanced prostate cancer, Clin. Transl. Sci., 5, 65, 10.1111/j.1752-8062.2011.00375.x Patsch, 2019, Monitoring dynamic cytotoxic chemotherapy response in castration-resistant prostate cancer using plasma cell-free DNA (cfDNA), BMC Res. Notes, 12, 275, 10.1186/s13104-019-4312-2 Mehra, 2018, Plasma Cell-free DNA Concentration and Outcomes from Taxane Therapy in Metastatic Castration-resistant Prostate Cancer from Two Phase III Trials (FIRSTANA and PROSELICA), Eur. Urol., 74, 283, 10.1016/j.eururo.2018.02.013 Liu, 2018, Assessment of Serum microRNA Biomarkers to Predict Reclassification of Prostate Cancer in Patients on Active Surveillance, J. Urol., 199, 1475 Alhasan, 2016, Circulating microRNA signature for the diagnosis of very high-risk prostate cancer, Proc. Natl. Acad. Sci. USA, 113, 10655, 10.1073/pnas.1611596113 Souza, 2017, Circulating mRNAs and miRNAs as candidate markers for the diagnosis and prognosis of prostate cancer, PLoS One, 12, 10.1371/journal.pone.0184094 Casadio, 2013, Urine cell-free DNA integrity as a marker for early prostate cancer diagnosis: a pilot study, Biomed. Res. Int., 2013, 10.1155/2013/270457 Salvi, 2015, Urine Cell-Free DNA Integrity Analysis for Early Detection of Prostate Cancer Patients, Dis. Markers, 2015, 10.1155/2015/574120 Loeb, 2010, PCA3 Urinary Biomarker for Prostate Cancer, Rev. Urol., 12, e205 Fernie, 2004, Metabolite profiling: from diagnostics to systems biology, Nat. Rev. Mol. Cell Biol., 5, 763, 10.1038/nrm1451 Yu, 2021, Identification of the metabolic signatures of prostate cancer by mass spectrometry-based plasma and urine metabolomics analysis, Prostate, 81, 1320, 10.1002/pros.24229 Zhao, 2017, Plasma metabolic profiling and novel metabolite biomarkers for diagnosing prostate cancer. 10.1039/C7RA04337F, RSC Adv., 7, 30060, 10.1039/C7RA04337F Li, 2016, High-throughput metabolomics to identify metabolites to serve as diagnostic biomarkers of prostate cancer. 10.1039/C6AY00127K, Anal. Methods, 8, 3284, 10.1039/C6AY00127K Snider, 2020, Identification of Plasma Glycosphingolipids as Potential Biomarkers for Prostate Cancer (PCa) Status, Biomolecules, 10, 1393, 10.3390/biom10101393 Xu, 2021, Serum Metabolic Profiling Identifies a Biomarker Panel for Improvement of Prostate Cancer Diagnosis. Original Research, Front. Oncol., 11 Xu, 2021, Metabolomics Profiling Discriminates Prostate Cancer From Benign Prostatic Hyperplasia Within the Prostate-Specific Antigen Gray Zone, Front. Oncol., 11, 10.3389/fonc.2021.730638 Khan, 2019, Noninvasive Serum Metabolomic Profiling Reveals Elevated Kynurenine Pathway's Metabolites in Humans with Prostate Cancer, J. Proteome Res., 18, 1532, 10.1021/acs.jproteome.8b00803 Lima, 2019, Identification of a biomarker panel for improvement of prostate cancer diagnosis by volatile metabolic profiling of urine, Br. J. Cancer, 121, 857, 10.1038/s41416-019-0585-4